US Patent 7,758,891 (Paclitaxel Albumin Nanoparticles + Gemcitabine for Pancreatic Cancer): Claim Scope, Patent Landscape, and Expiration/Challenge Risk
US Drug Patent 7,758,891 is a US method-of-treatment patent directed to pancreatic cancer therapy using paclitaxel albumin-coated nanoparticles (≤200 nm) in combination with gemcitabine, with multiple dependent claim hooks on dosing, scheduling, and nanoparticle/albumin specifics.
What does US Patent 7,758,891 claim cover for pancreatic cancer treatment?
Core claim (Claim 1) covers a combination regimen:
- Administer a composition of paclitaxel-coated nanoparticles with albumin, nanoparticle average diameter ≤200 nm, and
- Administer gemcitabine,
to a human individual with pancreatic cancer.
Distinctive claim-defining elements in Claim 1
- Therapeutic target: “method of treating pancreatic cancer in a human individual”
- Nanoparticle drug substance identity: paclitaxel coated with albumin
- Particle size: average diameter no greater than 200 nm
- Combination requirement: paclitaxel-albumin nanoparticle composition + gemcitabine, both administered as “effective amounts”
Practical reading: how broad is Claim 1?
Claim 1 is broad on:
- Pancreatic cancer stage (unless narrowed by dependent claims)
- Route of administration (not specified in your claim text)
- Gemcitabine scheduling (only narrowed in dependent Claims 10–11)
Claim 1 is narrow on:
- Particle size (≤200 nm)
- Composition class: paclitaxel nanoparticles coated with albumin (not merely albumin-containing formulations)
- Combination drug identity: gemcitabine is required
What does Claim 1 specifically require: paclitaxel-albumin nanoparticles size ≤200 nm plus gemcitabine?
Claim 1 is a “two-act” treatment claim: administer the nanoparticle composition and administer gemcitabine.
Particle size limitation (≤200 nm) drives infringement boundaries
- If a competitor’s albumin-coated paclitaxel nanoparticles have an average diameter above 200 nm, they can avoid the Claim 1 size limitation (assuming that the patent construction uses the “average diameter” as a strict element).
- If the product is a polydisperse distribution, claim coverage turns on measurement methodology (not addressed in the claim text you provided). From an enforcement perspective, this size requirement is a frequent battleground in chem/meas disputes.
Albumin-coated requirement is not “albumin excipient”
Claim 1 requires paclitaxel coated with albumin. That typically excludes:
- formulations where albumin is only a diluent/excipient without a coating relationship, unless a court construes “coated” broadly.
How do dependent claims narrow scope on scheduling and sequencing?
Your dependent claims add time structure.
Claim 2: sequential dosing
- Nanoparticle composition and gemcitabine are administered sequentially.
Claim 3: weekly dosing for both
- Both are administered weekly.
Claim 9 and Claim 10–11: interval vs gemcitabine frequency
- Claim 9: interval between nanoparticle administrations is less than a week.
- Claim 10: gemcitabine frequency is less than weekly.
- Claim 11: gemcitabine administered once every two weeks.
Implication for design-around
- A regimen that administers gemcitabine weekly (instead of <weekly) can potentially avoid Claims 10–11.
- If a regimen co-administers (not sequential) could avoid Claim 2, though Claim 1 may still be asserted if “administering” is construed to include simultaneous dosing.
- Claim 3 and Claims 9–11 create “matrix coverage” risk for specific trial schedules.
What dose ranges are protected: paclitaxel mg/m² and gemcitabine mg/m²?
Your dependent claims provide explicit dosing bands.
Paclitaxel nanoparticle dose ranges
- Claim 4: ~30 to 300 mg/m² paclitaxel in nanoparticle composition
- Claim 5: ~50 to 250 mg/m²
- Claim 6 / Claim 7: ~100 to 150 mg/m²
Gemcitabine dose range
- Claim 8: ~1000 to 2000 mg/m² gemcitabine
Dose design risk
- If an accused regimen uses paclitaxel-albumin nanoparticles within these bands, it increases alignment with dependent coverage.
- If the regimen uses paclitaxel outside those bands, Claim 1 may still be asserted if Claim 1 does not require a specific dose in your provided claim set. Your Claim 1 as provided only says “effective amount.” Dependent ranges can still matter for claim stacking or negotiation leverage.
What formulation/process specifics are required: albumin type and sterility/filterability?
Claim 12: albumin is human serum albumin
This narrows dependent claim scope to HSA-type albumin.
Claim 13: sterile filterable composition
Dependent claim coverage includes:
- nanoparticle composition that is sterile filterable
Design-around angles
- If a product is not filterable or is manufactured/handled in a way that challenges “sterile filterable” status, the dependent claim could be avoided, while Claim 1 (without that limitation) remains the larger threat if “effective amount” and “≤200 nm albumin-coated paclitaxel nanoparticles” are satisfied.
What is protected regarding albumin-to-paclitaxel weight ratio?
Claims 14–15: albumin:paclitaxel weight ratio bands
- Claim 14: albumin:paclitaxel about 1:1 to 18:1
- Claim 15: about 2:1 to 15:1
Impact
- These are formulation-parameter limitations that can matter in infringement if a competitor uses a different loading ratio.
- They also create a “claim ladder”: even if ratios differ, Claim 1 still covers “albumin-coated nanoparticles” without a ratio limitation.
What cancer subtypes are explicitly covered in dependent claims?
Claims 16–17
- Claim 16: metastatic pancreatic cancer
- Claim 17: advanced pancreatic cancer
These expand explicit clinical targeting but do not necessarily narrow Claim 1 unless a court requires the dependent claims’ limitations for those specific patient types.
What is the therapeutic endpoint language scope?
Claim 18
- Method amount is “effective to reduce tumor size”
This is a functional outcome element tied to “effective” dosing.
Infringement posture
- If clinical outcomes are used to argue effectiveness, it may be easier for plaintiffs when there is trial data showing tumor size reduction with the regimen.
- For defendants, differences in endpoints (or failure to show tumor size reduction) can complicate enforcement, though “effective” is often treated as a capability and not a guaranteed result.
How does the claim architecture create a “coverage ladder” for competitors?
Coverage by claim type
- Claim 1 sets the foundational combination:
- albumin-coated paclitaxel nanoparticles (≤200 nm) + gemcitabine
- Dependent claims then add specific:
- schedule (sequential, weekly, <weekly)
- dose bands (paclitaxel and gemcitabine)
- particle/material properties (HSA; sterile filterable)
- formulation parameter (albumin:paclitaxel ratio)
- clinical setting (metastatic/advanced)
- outcome framing (reduce tumor size)
Business implication
- If a competitor’s regimen matches the combination and particle size, Claim 1 is the immediate litigation target.
- If a competitor avoids Claim 1 (eg, by using nanoparticles with average diameter >200 nm or not albumin-coated), the remaining dependent claim hooks become less relevant because they all depend on Claim 1.
What prior art and related patent themes are likely adjacent (and why they matter)?
Without the patent’s specification and the cited prior art list, the landscape must be inferred from the claim scope itself. The technical themes that typically cluster around this type of combination include:
- Albumin-bound paclitaxel nanoparticle systems (albumin coating, particle size control, albumin loading)
- Combination regimens of paclitaxel derivatives with gemcitabine for pancreatic cancer
- Scheduling schemes (weekly vs every-two-weeks gemcitabine) and administration sequence
- Dose band patents tied to clinical protocols
These themes matter because they influence:
- whether there are earlier patents that anticipate the combination logic
- whether 7,758,891 is likely to be strong at Claim 1 or mainly at dependent claim parameter refinements
- what substitutes competitors can use while staying close to standard-of-care regimens
What would an enforcement and litigation map look like for US 7,758,891?
Given the claim text, enforcement typically targets defendants whose clinical protocols include:
- an albumin-coated paclitaxel nanoparticle product (≤200 nm) and
- gemcitabine in pancreatic cancer with a matching schedule/dose.
Litigation posture likely divides into two buckets
- Literal infringement on Claim 1:
- nanoparticle diameter ≤200 nm and albumin coating + gemcitabine combo
- Design-around failure on dependent claims:
- if particle size is covered, defendants then still face risks from schedule/dose/formulation parameters
Typical defense vectors implied by the claim text
- Particle sizing disputes (average diameter measurement)
- “Coated with albumin” disputes (coating vs bulk albumin exposure)
- Dosing/scheduling not matching dependent limitations (while still facing Claim 1)
How does US 7,758,891 compare with other pancreatic cancer gemcitabine combination patent strategies?
From a patent strategy perspective, this patent is aligned with a common combination format:
- a cytotoxic taxane (paclitaxel) delivered via a specialized nanoparticle (albumin-coated, size-limited)
- plus gemcitabine in pancreatic cancer.
Key differentiator: the ≤200 nm average diameter and albumin-coated paclitaxel nanoparticles are claim-defining.
For competitors using:
- nab-paclitaxel-like compositions with albumin binding,
- but with particle size outside the claimed ≤200 nm threshold,
- or with different taxane delivery without albumin coating,
the claim’s size and coating limitations are the central “gate.”
When does exclusivity end: patent expiration and regulatory exclusivity pathways?
The question of “when does it lose exclusivity” depends on:
- the patent’s filing date, and its term (20 years from earliest effective filing subject to adjustments) and any terminal disclaimers
- any pediatric exclusivity (unlikely to apply to method claims absent relevant triggers)
- the regulatory exclusivity status of the underlying drugs (gemcitabine is long off-patent; paclitaxel is generic)
- whether the formulation delivery system has separate IP
In the absence of the patent’s filing/priority date, expiration date, and regulatory Orange Book status, a precise exclusivity timeline cannot be produced from the claim text alone.
What generic entry risks exist for pancreatic cancer regimens using gemcitabine plus paclitaxel?
There is a structural asymmetry in the “generic entry” concept for a method patent:
- Gemcitabine is already generic.
- Paclitaxel is already generic.
- The protected element is the combination method and the specific nanoparticle form.
Accordingly, risk is not “gemcitabine generic entry” but rather:
- whether a generic or biosimilar-like substitute using an albumin-coated paclitaxel nanoparticle platform with ≤200 nm enters pancreatic cancer practice and uses the claimed regimen.
If a competitor uses:
- a different taxane nanoparticle platform not meeting “albumin-coated” or “≤200 nm,”
- or a different scheduling scheme that avoids certain dependent claims,
it may still face Claim 1 risk unless the fundamental nanoparticle element is avoided.
Which companies typically hold competing albumin-paclitaxel nanoparticle patent estates?
This section cannot be completed accurately without mapping:
- who owns the specific nanoparticle platform that corresponds to this claim family,
- whether 7,758,891 is part of that platform estate,
- and which companies hold later-generation improvements.
The claim text alone does not identify assignees, family members, or citation patterns. Without those, assigning a company list would be speculative.
How strong is the patent estate for US 7,758,891?
Strength is primarily a function of:
- claim breadth at Claim 1 (combination + particle size + albumin coating)
- whether prior art exists for:
- albumin-coated paclitaxel nanoparticles with ≤200 nm average diameter, and
- combination of paclitaxel formulations with gemcitabine in pancreatic cancer
- and whether the specification supports clear measurement and coating definitions
Based on the claim set provided, Claim 1 is strong on essential technical elements (coating + particle size + combination drug identity). However, strength at the “edge” depends heavily on:
- how prior art nanoparticles are characterized (average diameter distributions),
- and how “coated” is construed relative to albumin binding models.
How many patents likely cover the same regimen and which claim layers matter most?
Given the parameter-heavy dependent claims (size, dose bands, sequence/scheduling, albumin ratio, HSA type, sterile filterability), it is typical that the family includes:
- related method claims,
- formulation claims for nanoparticle composition,
- and manufacturing/purity/size control claims.
But the exact “how many” and whether they are in the same US family cannot be determined without:
- the patent family members and
- the related continuations/divisionals/cross-references.
A numeric count would require external patent data not present in your input.
Key Takeaways
- Claim 1 is the central protection: albumin-coated paclitaxel nanoparticles with average diameter ≤200 nm + gemcitabine for pancreatic cancer treatment.
- Dependent claims create a regimen-specific ladder covering sequence (sequential), timing (weekly vs every two weeks; nanoparticle intervals <1 week), and dose bands (paclitaxel mg/m²; gemcitabine mg/m²).
- Formulation/science constraints that can drive design-arounds are nanoparticle size, albumin coating, and (in dependent claims) HSA type, sterile filterability, and albumin-to-paclitaxel weight ratio.
- “Generic entry risk” for this patent is about whether any competing product platform delivers the claimed nanoparticle construct and is used in clinical practice with gemcitabine in a matching manner, not about gemcitabine/generics alone.
- A precise expiration/exclusivity and a company-by-company landscape require patent bibliographic fields and family mapping not included in the claim text.
FAQs
-
How can an accused regimen avoid infringement of Claim 1?
By not meeting at least one essential element: albumin-coated paclitaxel nanoparticles where the average diameter is ≤200 nm, or by not administering gemcitabine as part of the treated method for pancreatic cancer.
-
Do Claims 2–3 create additional protection beyond Claim 1?
Yes. They lock in sequence (sequential) and weekly dosing for both nanoparticle composition and gemcitabine, which can matter even when Claim 1 is contested.
-
What dosing changes most affect dependent claim risk?
Using paclitaxel and gemcitabine regimens outside the stated mg/m² bands and schedules can reduce alignment with dependent claims, though Claim 1 may still apply if “effective amount” and essential combination elements are met.
-
What is the most litigation-relevant technical measurement for the nanoparticle?
The average diameter limitation (≤200 nm). Any dispute over how diameter is measured and what the “average” is can be central.
-
Is the patent limited to metastatic or advanced pancreatic cancer?
Claim 1 covers pancreatic cancer broadly. Dependent claims specify metastatic and advanced pancreatic cancer, adding targeted coverage for those populations.
References
(No sources cited; the provided input contains the claim text only, and no bibliographic, prosecution, Orange Book, or litigation records were supplied.)
